 |
Technology Platforms Sustained product development is possible with our core technology platforms that include Biotransport™ and SP-MET-X™. Biotransport™ nanomedicine technology Involves the proprietary use of highly flexible block co-polymer chemistry to produce nanomedicine compositions of diverse molecules. Biotransport™ compositions consist of an active pharmaceutical ingredient (API) with specific polymer combinations resulting in beneficial biological response modification and targeted drug delivery. Biotransport™ compositions incorporate a drug molecule without chemical interactions; the resulting nano-systems, ranging from 10nm to 100nm in size, are formed spontaneously and are thermodynamically stable. This technology is applicable to new chemical entities and generic drugs and can be an effective tool for improving pharmacokinetics, bioavailability and provide drug life extension. SP-MET-X™ S100 pathway inhibition
S100A4 and some other S100 proteins are known biomarkers recently identified as unique targets in a pathway that occurs early in the signal transduction cascade leading to metastasis formation and cancer progression. SP-MET-X™ technology includes a new library of small molecules that embodies a number of new chemical entities (NCEs) with variable pharmacological properties that inhibit the newly identified pathogenic pathway mediated by the S100 proteins. S100 proteins play a significant role in promoting growth and the spread of cancers with poor prognosis. Tumors that overexpress these proteins include malignant melanoma, colorectal, breast, bladder, pancreatic, gastric and esophageal cancers. A new library of S100 targeted compounds has been created, from which several NCEs have been identified to be effective against this novel cancer target. The synthesized compounds are small molecules, with low toxicities, that are orally bioavailable and show good chemical and metabolic stabilities. A set of selected compounds is undergoing pre-clinical development. |
